“…Therapeutics based on small interfering RNA (siRNA), in particular, display diminished adverse effects when compared with conventional chemotherapeutics. , This is because naked siRNA typically has poor stability in blood, do not enter cells by themselves, and are easily degradable in endo/lysosomes . A major challenge in clinical translation arises from the lack of effective and nontoxic delivery vehicles that can protect against ubiquitous RNase and achieve endo/lysosomal escape for effective release of siRNAs into the cytoplasm. , Accordingly, numerous delivery systems, for example, lipids, − cyclodextrin, nanogels, chitosan, cationic polymers, − cationic polyrotaxanes, − ionizable amphiphilic dendrimer, , inorganic materials, − and electroporation have been considered and studied to realize RNA-based therapeutics. Conventional nanocarriers, however, generally fail to simultaneously achieve desirable endo/lysosomal rupture and effective siRNA protection. , Ideal vectors for delivery thus constitute an unmet need to which the innovative design and application of materials capable of self-assembly with siRNA have much to contribute.…”